Literature DB >> 1926027

Creatine kinase activity in patients with brittle asthma treated with long term subcutaneous terbutaline.

A P Sykes1, N Lawson, J A Finnegan, J G Ayres.   

Abstract

Infused beta 2 agonists have been shown to cause focal myocardial necrosis. Serum creatine kinase activity was compared in 13 patients with brittle asthma currently being treated with subcutaneous terbutaline and an age and sex matched control group of patients with moderate asthma having inhaled treatment only. The median serum total creatine kinase activity for patients receiving subcutaneous terbutaline (211 units/l) was greater than that for the control group (120 units/l). The cardiac specific isoenzyme component of creatine kinase was not raised in either group, and the electrocardiograms and serum aspartate aminotransferase activity were normal. Electromyograms in five patients receiving subcutaneous terbutaline with high creatine kinase activity showed changes consistent with myositis in two, one of whom was subsequently shown to have a metabolic myopathy, which is thought to be long standing. No pathological changes were seen in the myocardium at necropsy in a patient who died from an acute attack of asthma while taking subcutaneous terbutaline. These results suggest that the raised creatine kinase activity seen in patients receiving this treatment is unlikely to be myocardial in origin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1926027      PMCID: PMC463281          DOI: 10.1136/thx.46.8.580

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  15 in total

1.  Creatine kinase in serum: 1. Determination of optimum reaction conditions.

Authors:  G Szasz; W Gruber; E Bernt
Journal:  Clin Chem       Date:  1976-05       Impact factor: 8.327

2.  L-Norepinephrine myocarditis.

Authors:  J E SZAKACS; A CANNON
Journal:  Am J Clin Pathol       Date:  1958-11       Impact factor: 2.493

3.  [Determination of creatine kinase-MB in serum using inhibiting antibodies (author's transl)].

Authors:  U Würzburg; N Hennrich; H Lang; W Prellwitz; D Neumeier; M Knedel
Journal:  Klin Wochenschr       Date:  1976-04-15

4.  Serum creatine phosphokinase activity in asthma.

Authors:  N K Burki; L Diamond
Journal:  Am Rev Respir Dis       Date:  1977-08

5.  Long term treatment of severe asthma with subcutaneous terbutaline.

Authors:  B R O'Driscoll; S P Ruffles; J G Ayres; G M Cochrane
Journal:  Br J Dis Chest       Date:  1988-10

6.  Pitfalls in interpreting serum creatine phosphokinase activity.

Authors:  M A Nevins; M Saran; M Bright; L J Lyon
Journal:  JAMA       Date:  1973-06-04       Impact factor: 56.272

7.  Blood studies in untreated patients with acute asthma.

Authors:  M S Karetzky
Journal:  Am Rev Respir Dis       Date:  1975-11

8.  Subcutaneous terbutaline and control of brittle asthma or appreciable morning dipping.

Authors:  J Ayres; D R Fish; D C Wheeler; J Wiggins; G M Cochrane; C Skinner
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-09

9.  Drug-induced left ventricular failure in patients with pulmonary disease. Endomyocardial biopsy demonstration of catecholamine myocarditis.

Authors:  A F Nino; M M Berman; E H Gluck; M M Conway; J P Fisher; J E Dougherty; M A Rossi
Journal:  Chest       Date:  1987-10       Impact factor: 9.410

10.  Regular inhaled beta-agonist treatment in bronchial asthma.

Authors:  M R Sears; D R Taylor; C G Print; D C Lake; Q Q Li; E M Flannery; D M Yates; M K Lucas; G P Herbison
Journal:  Lancet       Date:  1990-12-08       Impact factor: 79.321

View more
  1 in total

Review 1.  Brittle asthma.

Authors:  J G Ayres; J F Miles; P J Barnes
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.